Analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will announce ($0.44) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.28). Heron Therapeutics reported earnings per share of ($0.97) in the same quarter last year, which suggests a positive year-over-year growth rate of 54.6%. The company is scheduled to report its next earnings report on Tuesday, February 26th.
On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.34) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($2.18). For the next financial year, analysts anticipate that the company will post earnings of ($0.80) per share, with EPS estimates ranging from ($1.44) to $0.03. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The business had revenue of $19.79 million for the quarter, compared to analyst estimates of $19.84 million. During the same quarter in the prior year, the company earned ($0.77) earnings per share. The company’s quarterly revenue was up 130.9% on a year-over-year basis.
Heron Therapeutics stock opened at $27.88 on Friday. Heron Therapeutics has a one year low of $15.00 and a one year high of $42.90. The stock has a market cap of $2.18 billion, a PE ratio of 7.64 and a beta of 1.48.
In related news, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $32.07, for a total transaction of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares of the company’s stock, valued at $192,420. The disclosure for this sale can be found here. Insiders sold a total of 2,701,494 shares of company stock valued at $96,553,796 over the last quarter. 16.20% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. MYDA Advisors LLC acquired a new stake in Heron Therapeutics during the second quarter worth approximately $354,000. FMR LLC lifted its position in Heron Therapeutics by 6.5% during the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after acquiring an additional 693,699 shares during the last quarter. Castleark Management LLC lifted its position in Heron Therapeutics by 237.5% during the second quarter. Castleark Management LLC now owns 201,080 shares of the biotechnology company’s stock worth $7,812,000 after acquiring an additional 141,505 shares during the last quarter. Orbimed Advisors LLC lifted its position in Heron Therapeutics by 15.4% during the second quarter. Orbimed Advisors LLC now owns 1,315,100 shares of the biotechnology company’s stock worth $51,092,000 after acquiring an additional 175,300 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Heron Therapeutics by 21.4% during the second quarter. Northern Trust Corp now owns 762,315 shares of the biotechnology company’s stock worth $29,616,000 after acquiring an additional 134,247 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.